Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel financing round led exclusively by Dalton Venture. The proceeds will be utilized for the extraction of high-purity active collagen, the in-depth development of oral bone tissue-guided membrane adhesive and artificial cornea, and the establishment of a magnification platform.
Company and Technology Overview
Founded in 2022 in Suzhou, Bochuang Bio is poised to develop high-end artificial cornea, periosteum, dura, nerve sheath, and other novel products. The company is leveraging its first-in-class “electrochemical deposition of biological macromolecules” (EDP) technology platform to drive innovation in these areas.
Future Development and Goals
The funding will accelerate Bochuang Bio’s efforts to enhance its product offerings and expand its capabilities in the medical technology sector. With the support of Dalton Venture, the company aims to establish itself as a leader in the development of advanced medical products that improve patient outcomes and address unmet medical needs.-Fineline Info & Tech
